StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
IGCIGC Pharma, Inc.
stockpulse.co.kr
NYSE
$0.2465▼ 1.36%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $25.7MShares out 100M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

9
  • 2d agoAfter-hours26.10.23 05:02
    DEFA14AOther#●●●

    IGC Pharma, Inc.

    IGC Pharma, Inc. has filed additional proxy solicitation materials (DEFA14A) regarding its upcoming shareholder meeting. This filing is a procedural document intended to encourage shareholder voting and does not contain any material changes to the company's financial status or corporate governance.…more

    $0.2465-1.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 3d agoPre-market26.10.22 09:32filed
    DEF 14AOther

    IGC Pharma, Inc.

    IGC Pharma completed 100% of enrollment for its Phase 2 CALMA trial of IGC-AD1 on September 28, 2026, with final dosing expected in November. For the nine-month period ended December 31, 2025, the company reported $869,000 in revenue and a net loss of $4.146 million. Additionally, management converted approximately $1.15 million in debt owed to them into common stock, continuing the company's practice of funding operations through share issuance.…more

    $0.2465-1.36%vs prev close
    View filingShare
  • 9.29After-hours26.09.30 05:01
    4Ownership

    IGC Pharma, Inc.

    Insider Mukunda Ram of IGC Pharma, Inc. filed a Form 4 on September 29, 2026, reporting changes in beneficial ownership of securities effective as of September 25, 2026. This filing provides the official record of the insider's stock transaction activity.…more

    $0.2465-1.36%vs prev close
    View filingShare

8 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.28Pre-market26.09.28 21:04
    #●●●#●●●

    IGC Pharma Completes Patient Enrollment for Phase 2 Alzheimer's Trial

    IGC Pharma has finished enrolling 168 patients for its Phase 2 clinical trial of IGC-AD1 targeting Alzheimer's agitation. The company expects to report topline data in the fourth quarter of 2026.…more

    $0.2465-1.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga